PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration
Authors:
Preprint
- 14 May 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Invasion and migration are the key hallmarks of cancer, and aggressive growth is a major factor contributing to treatment failure and poor prognosis in glioblastoma. Protein arginine methyltransferase 6 (PRMT6), as an epigenetic regulator, has been confirmed to promote the malignant proliferation of GBM cells in previous studies. However, the effects of PRMT6 on GBM cell invasion and migration and its underlying mechanisms remain elusive. Here, we report that PRMT6 functions as a driver element for tumor cell invasion and migration in glioblastoma. Bioinformatics analysis and glioma sample detection results demonstrated that PRMT6 is highly expressed in mesenchymal subtype or invasive gliomas, and is significantly negatively correlated with their prognosis. Inhibition of PRMT6 (using PRMT6 shRNA or inhibitor EPZ020411) reduces GBM cell invasion and migration in vitro, whereas overexpression of PRMT6 produces opposite effects. Then, we identified that PRMT6 maintains the protein stability of EZH2 by inhibiting the degradation of EZH2 protein, thereby mediating the invasion and migration of GBM cells. Further mechanistic investigations found that PRMT6 inhibits the transcription of TRAF6 by activating the histone methylation mark (H3R2me2a), and reducing the interaction between TRAF6 and EZH2 to enhance the protein stability of EZH2 in GBM cells. Xenograft tumor assay and HE staining results showed that the expression of PRMT6 could promote the invasion of GBM cells in vivo, the immunohistochemical staining results of mouse brain tissue tumor sections also confirmed the regulatory relationship between PRMT6, TRAF6, and EZH2. Our findings illustrate that PRMT6 suppresses TRAF6 transcription via H3R2me2a to enhance the protein stability of EZH2 to facilitate GBM cell invasion and migration. Blocking the PRMT6-TRAF6-EZH2 axis is a promising strategy for inhibiting GBM cell invasion and migration.Keywords
All Related Versions
- Version 1, 2024-05-14, Research Square
- Published version: Cell Death & Disease, 15 (7), 1.
This publication has 56 references indexed in Scilit:
- EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospectsBiomedicine & Pharmacotherapy, 2022
- PRMT6 promotes endometrial cancer via AKT/mTOR signaling and indicates poor prognosisThe International Journal of Biochemistry & Cell Biology, 2020
- Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated GenesCell Reports, 2018
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid TumorsCell, 2018
- Downregulation of Ezh2 methyltransferase by FOXP3: New insight of FOXP3 into chromatin remodeling?Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteinsBiochemical and Biophysical Research Communications, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Sensing invasion: Cell surface receptors driving spreading of glioblastomaJournal of Cellular Physiology, 2009
- Diffuse glioma growth: a guerilla warActa Neuropathologica, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007